High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.

ABSTRACT:

Background and objectives

Different rituximab protocols are used to treat membranous nephropathy. We compared two rituximab protocols in patients with membranous nephropathy.

Design, setting, participants, & measurements

Twenty-eight participants from the NICE cohort received two infusions of 1-g rituximab at 2-week intervals, whereas 27 participants from the Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Membranous Nephropathy (GEMRITUX) cohort received two infusions of 375 mg/m² at 1-week interval. We measured serum rituximab levels and compared remission at month 6 and before any treatment modification and analyzed factors associated with remission and relapses.

Results

Remissions occurred in 18 (64%) versus eigh

SUBMITTER: Seitz-Polski B 

PROVIDER: S-EPMC6682825 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature